Ratings argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 15:11:36 11/07/2025 BST			5-day change	1st Jan Change
480.50 ^EUR	-1.01%		+4.41%	-19.88%

07-08	Deutsche Bank Upgrades Argenx to Buy, Raises PT	MT
07-08	European shares flat as investors assess new US tariff proposals	RE

Summary: argenx SE

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Highlights: argenx SE

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: argenx SE

With an expected P/E ratio at 49.68 and 27.96 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings Chart: argenx SE

Source: Surperformance

ESG chart: argenx SE

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	ARGENX SE				34.72B
	WUXI APPTEC CO., LTD.				28B
	GENMAB A/S				13.43B
	WUXI BIOLOGICS (CAYMAN) INC.				13.32B
	AKESO, INC.				12.38B
	EXELIXIS, INC.				12.32B
	Average				19.03B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes